Physician profile
Tka Edwards
NPI 1457061871
$2,768.25
in general payments reported to CMS, 2019-2025
10 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $170 · 2024: $1,080 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,371.15 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $330.00 | 2024-2025 | |
| Amgen INC. | $287.72 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $199.43 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $193.59 | 2024-2025 | |
| Dexcom, INC. | $173.57 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2024 | Wainua |
| Pfizer INC. | $40.24 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $27.56 | 2025 | Zoryve |
| Lilly USA, LLC | $19.98 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tka Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.